Effective January 1, 2026, AmeriHealth Insurance Company of New Jersey (AmeriHealth) will be implementing the following updates to its Medicare Part D drug program:
- Adalimumab-AACF will be the preferred biosimilar for Humira® (adalimumab).
- Tyenne (tocilizumab-aazg) will be the preferred biosimilar for Actemra® (tocilizumab).
How will this affect your patients (our members)?
Humira
- Pharmacy Benefit:
- Humira will be removed from the AmeriHealth Medicare Part D formulary and designated as non-formulary.
- The preferred adalimumab product will be adalimumab-AACF, a lower-cost biosimilar of Humira. Members were notified of this change by mail.
- All existing authorizations for Humira will be transitioned to adalimumab-AACF beginning January 1, 2026.
Actemra
- Pharmacy Benefit:
- Actemra will be removed from the AmeriHealth Medicare Part D formulary and designated as non-formulary.
- The preferred tocilizumab product will be Tyenne (tocilizumab-aazg), a lower-cost biosimilar of Actemra. We notified our members of this change by mail.
- All existing authorizations for Actemra will be transitioned to Tyenne beginning January 1, 2026.
Learn more
For more information about biosimilar and formulary changes, visit the Pharmacy Resource page.
25-0291